secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001193125-23-153420
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon ARCHER Ph2: ANX007 shows stat-sig vision loss protection, primary lesion growth endpoint missed
--------------------------------------------------------------------------------

- ANX007 monthly reduced risk of ≥15-letter BCVA loss by 72% (p=0.006); pooled 59% (p=0.008).
- Primary endpoint GA lesion growth rate reduction not met: monthly 6.2% (p=0.526), EOM 1.3% (p=0.896).
- ANX007 well-tolerated; 3 SAEs endophthalmitis (injection-related), 3 SAEs intraocular inflammation suspected treatment-related.
- First complement therapy to show preservation of visual function in a prospective 12-month GA trial.
- Company plans regulatory engagement for optimal path forward; webcast today 1:30pm PT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523153420/0001193125-23-153420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523153420/d468662d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-153420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer